Sublingual Immunotherapy

Sublingual immunotherapy for house dust mites improved allergic rhinitis symptoms over a 1-year period among children aged 1 to 4 years, according to results from an open-label study..

Sublingual immunotherapy for house dust mite allergy improved allergic rhinitis symptoms among children aged 1 to 4 years over 12 months, according to a study published in Pediatric Allergy and Immunology.

The field of food allergy treatment has been evolving rapidly, with several promising developments in recent years. Typically, much of what makes headlines, though, surrounds who pays for the headlines.

Children at high risk for reactions in oral immunotherapy for food allergy may benefit from sublingual immunotherapy before oral food challenges, according to a study published in the Journal of Allergy and Clinical Immunology: In Practice.

Sublingual immunotherapy tablets improved quality of life for patients with allergic rhinitis with and without conjunctivitis, according to a review published in The Journal of Allergy and Clinical Immunology: In Practice.

Insect venom was the cause of 82.7% of cases of occupational anaphylaxis, followed by food, drugs and latex, according to a study published in Allergy.

Children who begin sublingual immunotherapy for allergic rhinitis at age 5 years have less risk for developing allergic asthma than children who begin this treatment later, according to a study published in Allergy.

Sublingual immunotherapy was safe and effective in inducing desensitization and remission of peanut allergy in children aged 1 to 4 years, according to a study published in The Journal of Allergy and Clinical Immunology.

Sublingual immunotherapy for house dust mite allergic asthma improved bronchial epithelial antiviral resistance to viral infection, according to a study published in the American Journal of Respiratory and Critical Care Medicine.

Sublingual immunotherapy for peanut allergy was safe and effective among children aged 2 to 12 years, making it a promising alternative to oral immunotherapy, according to a study published in The Journal of Allergy and Clinical Immunology.